Document Detail


Correlation among systemic inflammatory parameter, occurrence of delayed neurological deficits, and outcome after aneurysmal subarachnoid hemorrhage.
MedLine Citation:
PMID:  23208059     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The role and impact of systemic inflammatory response after aneurysmal subarachnoid hemorrhage remain to be elucidated.
OBJECTIVE: To assess the time course and correlation of systemic inflammatory parameters with outcome and the occurrence of delayed ischemic neurological deficits (DINDs) after subarachnoid hemorrhage.
METHODS: Besides the baseline characteristics, daily interleukin-6 (IL-6), procalcitonin, C-reactive protein levels, and leukocyte counts were prospectively measured until day 14 after subarachnoid hemorrhage. Occurrence of infectious complications and application of therapeutic hypothermia were assessed as confounding factors. The primary end point was outcome after 3 months, assessed by Glasgow outcome scale; the secondary end point was the occurrence of DINDs.
RESULTS: During a 3-year period, a total of 138 patients were included. All inflammatory parameters measured were higher in patients with unfavorable outcome (Glasgow outcome scale score, 1-3). After adjustment for confounding factors, elevated IL-6 and leukocyte counts remained significant risk factors for unfavorable outcome. The odds ratio for log IL-6 was 4.07 (95% confidence interval, 1.18 to 14.03; P = .03) and for leukocyte counts was 1.24 (95% confidence interval, 1.06-1.46, P = .008). The analysis of the time course established that IL-6 was the only significantly elevated parameter in the early phase in patients with unfavorable outcome. Higher IL-6 levels in the early phase (days 3-7) were associated with the occurrence of DINDs. The adjusted odds ratio for log IL-6 was 4.03 (95% confidence interval, 1.21-13.40; P = .02).
CONCLUSION: Higher IL-6 levels are associated with worse clinical outcome and the occurrence of DINDs. Because IL-6 levels were significantly elevated in the early phase, they might be a useful parameter to monitor.
Authors:
Carl Muroi; Michael Hugelshofer; Martin Seule; Ilhan Tastan; Masayuki Fujioka; Kenichi Mishima; Emanuela Keller
Related Documents :
14961909 - Psoriasis induced by topical imiquimod.
20073999 - Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative.
6736339 - Bilateral comparison of generalized lichen planus treated with psoralens and ultraviole...
7248179 - Low-dose puva maintenance in psoriasis following ingram therapy.
24578259 - A 4-years monitoring of hypoderma diana in horses from the czech republic.
12775319 - Cyclosporin in childhood psoriasis.
10665719 - Op-1 for cervical spine fusion: bridging bone in only 1 of 4 rheumatoid patients but pr...
24471359 - Risk factors for subsequent impaired driving by injured passengers.
20678799 - Ranibizumab for choroidal neovascularization secondary to causes other than age-related...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurosurgery     Volume:  72     ISSN:  1524-4040     ISO Abbreviation:  Neurosurgery     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-18     Completed Date:  2013-08-02     Revised Date:  2013-11-08    
Medline Journal Info:
Nlm Unique ID:  7802914     Medline TA:  Neurosurgery     Country:  United States    
Other Details:
Languages:  eng     Pagination:  367-75; discussion 375     Citation Subset:  IM    
Affiliation:
Neurocritical Care Unit, Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland. carl.muroi@hispeed.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Biological Markers
Brain Ischemia / etiology,  pathology
C-Reactive Protein / metabolism
Calcitonin / blood
Cerebral Angiography
Confidence Intervals
Endpoint Determination
Female
Glasgow Outcome Scale
Humans
Hypothermia, Induced
Inflammation / blood,  pathology*
Interleukin-6 / blood
Leukocyte Count
Logistic Models
Male
Middle Aged
Nervous System Diseases / etiology*,  pathology*
Odds Ratio
Prospective Studies
Protein Precursors / blood
ROC Curve
Sample Size
Subarachnoid Hemorrhage / complications*,  pathology*,  therapy
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Interleukin-6; 0/Protein Precursors; 56645-65-9/procalcitonin; 9007-12-9/Calcitonin; 9007-41-4/C-Reactive Protein
Comments/Corrections
Erratum In:
Neurosurgery. 2013 Oct;73(4):E753

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Continued Concern of Parent Vessel Steno-occlusive Progression with Onyx HD-500 and the Utility of Q...
Next Document:  Current Management of Middle Cerebral Artery Aneurysms: Surgical Results with a "Clip First" Policy.